Transcatheter Mitral Valve Repair And Replacement MarketSize and Trends

Transcatheter mitral valve repair and replacement methods are gaining significant traction due to advances in valve therapy. Transcatheter Mitral Valve Replacement (TMVR) can be used as an alternative to open-heart surgery and is used in treating mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.

Transcatheter Mitral Valve Repair and Replacement Market Drivers

Increasing mortality due to chronic and cardiovascular diseases especially in the elderly population is a major factor boosting the growth of the market. As per the American Heart Association estimates in 2017, around 19.1 million death occur annually worldwide due to various cardiovascular diseases. Furthermore, as per the United Nations (UN) estimates 2017, the geriatric population in the U.S. is expected to reach over 72 million by 2022. The growth of this target population coupled with increasing risk of cardiovascular diseases is expected to drive the growth of the market.

The global transcatheter mitral valve repair and replacement devices market is expected to witness growth, owing to continuous technological advancements such as developing multiple use valves. For instance, in June 2017, Edwards Lifesciences received FDA approval for its SAPIEN 3 transcatheter prosthetic heart valve, indicated for placement within both mitral valves and aortic valves.

Increase in number of TMVR pipeline devices for treatment of mitral valve abnormalities are also expected to propel growth of TMVR market. For instance, a randomized clinical trial of Medtronic Intrepid Transcatheter Mitral Valve Replacement System, sponsored by Medtronic Cardiovascular is ongoing for treating mitral valve regurgitation and is estimated to complete in October 2025.

Furthermore, in September 2018, Venus Medtech (Hangzhou) Inc., a China-based heart valve developer, acquired Israel-based medical device firm, Keystone Heart Ltd for Keystone’s TriGUARD 3 device, which is used to prevent cerebral embolism during Transcatheter mitral valve repair and replacement. This acquisition provides an opportunity for Venus Medtech to expand their portfolio in other regions especially in the U.S. and Europe, Middle East, and Africa regions.